Oh, but we used mathematical models to pick the dose, they said.
by Meryl Nass
Published on my blog on June 14, 2020 (before most people could grasp what was happening) and edited on March 24, 2022
The Solidarity Trial is a WHO-led conglomeration of many national trials of treatments for Covid-19. In March 2020 alone, the WHO collected $108 million from donors to cover the costs of its Solidarity clinical trials. After the overdosing was exposed, WHO claimed it paid for the trial itself, perhaps to cover for a donor?
Per the WHO:
As of 3 June 2020, more than 3500 patients have been recruited in 35 countries, with over 400 hospitals actively recruiting patients. Overall, over 100 countries have joined or expressed an interest in joining the trial, and WHO is actively supporting 60 of them…
The hydroxychloroquine arm of the Solidarity trials restarted enrolling patients June 3, after being halted May 25 by WHO Director-General Dr. Tedros Adhanom Ghebreyesus and the Executive Group of the Solidarity Trial. The hydroxychloroquine (HCQ) arm of the trials had been stopped after publication of the Lancet Surgisphere study, which claimed that patients who received chloroquine or hydroxychloroquine had 35% higher death rates, but the Lancet study was retracted 13 days after publication, as its data turned out to be fabricated. The HCQ Solidarity trials restarted after the retraction and were currently ongoing in June 2020. [However, the international outpatient HCQ trial sponsored by Oxford (COP COV) was not allowed to resume then.]
Below are the drugs being tested in Solidarity:
● Lopinavir with Ritonavir
● Lopinavir with Ritonavir plus Interferon beta-1a.
Initially, the WHO planned to use neither cloroquine drug in its trials. But multiple countries requested chloroquines, so both chloroquine (CQ) and HCQ were then added to the trial plan. However, HCQ was felt to be a little safer, countries preferred it, so WHO dropped CQ from its trials. Other clinical trials continue to test both CQ and HCQ against Covid-19. Read More